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Abstract
Bacterial pneumonia is a common contributor to severe outcomes of inﬂuenza. Epidemiological data suggest that the incidence, severity and
associated bacterial pathogens differ between epidemics and by geographical location within epidemics. Data from animal models
demonstrate that differences in both viral and bacterial strains alter the incidence and outcomes of pneumonia. For inﬂuenza viruses,
evolutionary changes to speciﬁc virulence factors appear to alter the ability of viruses within particular lineages to prime the host for
secondary bacterial infection. Although bacterial strains differ considerably in disease potential in the setting of viral co-infection, the
bacterial virulence factors underlying this ﬁnding are currently unknown. The hypothesis that geographical variation exists in the prevalence
of bacterial strains expressing factors that enable efﬁcient disease potentiation during viral epidemics should be considered as one
explanation for regional differences in severity. This would have implications for surveillance, vaccine development, and the conduct of
clinical trials for the prevention or treatment of pneumonia.
Keywords: Inﬂuenza, mouse model, pneumonia, Staphylococcus aureus, Streptococcus pneumoniae
Article published online: 10 December 2012
Clin Microbiol Infect 2013; 19: 113–118
Corresponding author: J. A. McCullers, Department of Pediatrics,
University of Tennessee Health Sciences Center, 50 N. Dunlap St,
Memphis, TN 38103, USA
E-mail: jmccullers@uthsc.edu
History, Background, and Epidemiology
The ﬁrst documentation of viral–bacterial superinfections has
been attributed to the French physician R. T. H. Laennec, who
practised in Paris at the dawn of the 19th century. He noted an
increased incidence of typical lobar pneumonia occurring in
patients suffering from inﬂuenza [1]. Although it is now well
recognized that secondary bacterial pneumonia is a frequent
cause of excess mortality during inﬂuenza epidemics, the
epidemiology remains frustratingly unclear. This stems from
two basic problems: mortality resulting from inﬂuenza and
pneumonia cannot be disentangled within standard reporting
structures; and it remains exceedingly difﬁcult to accurately
establish the aetiology of pneumonia [2,3]. Excess mortality,
i.e. deaths occurring during an inﬂuenza epidemic in excess of
the baseline deaths expected for the time of year, is used as an
estimate of attributable mortality for the virus, because a
deﬁnitive diagnosis of inﬂuenza is not available from death
certiﬁcates. Determining the proportion associated with
pneumonia, or with another cause of death such as a cardiac
complication, is difﬁcult or impossible. In addition, excess
mortality statistics only encompass the most severe cases and
outcomes, and the greater burden of disease in outpatient and
hospital settings goes largely undeﬁned. The advent of nucleic
acid-based diagnostics for viral pathogens is greatly expanding
our knowledge of viral contributors to these interactions, and
leading to an increased appreciation that many, if not most,
pneumonias result from co-infections [3]. Diagnostics for
bacterial causes of lower respiratory infection, however,
remain severely limited, because of both sensitivity issues (an
inability to easily access the lower respiratory tract and
determine which pathogens are present) and speciﬁcity
problems (some of the most common pneumonic bacterial
pathogens also colonize the nasopharynx, limiting the utility of
sampling of the upper respiratory tract to establish causation
in the lower respiratory tract). In addition, the use of
antibiotics prior to sampling may obscure a potential bacte-
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rial aetiology when culture techniques are used for diagnosis
[4].
The WHO has estimated that inﬂuenza epidemics cause 3–
5 million severe illnesses and 250 000–500 000 deaths each
year in industrialized countries [5]. The impact in the
developing world is unknown. In typical epidemic years,
approximately one-quarter of these deaths are thought to be
caused by secondary bacterial pneumonia [6] (reviewed in [7]).
However, these estimates are derived from large-scale pop-
ulation data that were not intended to separate out pneumonia
deaths and that vary greatly by season and circulating strain.
No deﬁnitive studies have been performed. Better data are
available from the three inﬂuenza pandemics of the 20th
century, in which bacterial aetiologies were identiﬁed in 50–
95% of patients with fatal or life-threatening pneumonia [7–10].
In the modern era, the inﬂuenza A virus H1N1 pandemic of
2009 provided an opportunity to study the epidemiology of
serious secondary infections in greater detail than had
previously been possible. Bacterial co-infections were found
as a complication of inﬂuenza in 25–56% of well-characterized
severe or fatal cases in selected studies [4,11–15]. Detection of
bacteria such as Streptococcus pneumoniae was associated with
a worse outcome [16]. Overall, these data suggest that
secondary bacterial pneumonia is more common during the
circulation of pandemic strains than during inter-pandemic
inﬂuenza epidemics, although the dearth of data on complica-
tions of seasonal inﬂuenza makes exact comparisons difﬁcult.
If data are scant on the most studied pairing, inﬂuenza and
S. pneumoniae, they are even more scarce on the association
between other respiratory viruses and pneumococcal disease
(reviewed in [8]). Large studies that have attempted to
comprehensively detect both viruses and bacteria have dem-
onstrated that such viral–bacterial co-infections do occur, but
detailed information on speciﬁc pairings has typically not been
reported [17–20]. A recent study of community-acquired
pneumonia in hospitalized children in Taiwan showed frequent
S. pneumoniae co-infection in children with respiratory viruses,
including respiratory syncytial virus (RSV), inﬂuenza A virus,
parainﬂuenza viruses, and adenoviruses, although proven cases
of pneumococcal infection were not reported separately from
probable cases identiﬁed through examination of oropharyn-
geal specimens [21]. A study of RSV in hospitalized children in
Brazil demonstrated a statistically signiﬁcant association
between infection with the virus and isolation of bacteria
from sterile sites as compared with RSV-negative children, but
many of the recovered bacteria would not be considered
typical pneumonic pathogens [22]. Very few data on the
frequency of respiratory virus co-infection with other bacterial
causes of pneumonia are available. Overall, although such
infections are known to occur, there is a paucity of data on the
frequency of secondary bacterial infections in persons infected
with viruses other than inﬂuenza virus. Likewise, the clinical
signiﬁcance of these co-infections is not known.
Staphylococcus aureus, S. pneumoniae and Streptococcus pyog-
enes (group A streptococcus) are the most common bacterial
pathogens that complicate inﬂuenza (reviewed in [7,23]).
Streptococcus pneumoniae is the most frequently identiﬁed
secondary pathogen in most case series, including those from
the 1918 pandemic (Fig. 1) [9]. Staphylococcus aureus was the
most prominent aetiological agent in the 1957 pandemic
[24–26], and has been a more common cause of pneumonia
since the emergence of the USA300 clonotypes in regions
FIG. 1. Timeline of circulating inﬂuenza strains and related complications since 1918. The bacterial species most commonly isolated from serious or
fatal cases of disease are listed for each pandemic. Notes: (i) signiﬁcant geographical variation in the relative frequency of bacterial pathogens existed
within pandemics, as discussed in the text; (ii) the broken blue line indicates that, although inﬂuenza B virus was not isolated until 1940, it is inferred
to have circulated prior to this time; (iii) although the ﬁrst isolation of an inﬂuenza A virus was in 1933, the 1918 pandemic strain has been
resurrected from frozen material; (iv) the seasonal H1N1 strain that re-emerged in 1977 is most similar to viruses that circulated around 1950; the
2009 ‘swine’ H1N1 has an H1 haemagglutinin that differs phylogenetically from that in the previously circulating human H1N1 strains.
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where these strains predominate [27]. Widespread use of
pneumococcal vaccines in developed countries may be altering
the relative frequency of these two bacteria, both by
decreasing the absolute incidence of pneumococcal infections,
and by changing the dynamics of staphylococcal colonization
and invasion through alterations to the nasopharyngeal ﬂora.
Group A streptococcus is entirely absent from some case
series, and is typically third in incidence when it appears [28].
Haemophilus inﬂuenzae, a frequent cause of secondary bacterial
pneumonia in the early part of the 20th century, is less
common, particularly in children, with the advent of the type B
conjugate vaccine. Non-typeable strains are still signiﬁcant
causes of acute otitis media associated with infections by
inﬂuenza virus and other respiratory viruses, and can be minor
causes of virus-associated community-acquired pneumonia in
adults [29] or in children where vaccination is not widespread
[30]. The relative rank order of the top three secondary
pathogens differs by inﬂuenza epidemic and between studies
within an epidemic. Considerable regional variation was seen
during the 1918 pandemic [31]. Although the precise reasons
are presently unclear, this geographical variation in disease
aetiology suggests that both strain-related differences in the
ability to prime the host for bacterial infections and regional
differences in the distribution and make-up of the participating
pathogens contribute to the incidence and aetiology of
secondary bacterial pneumonia.
Modelling Co-infections in Animals
The difﬁculties in precisely establishing the aetiology of
pneumonia in humans and associated problems in understand-
ing the epidemiology of secondary bacterial infections have led
to the use of animals to investigate virus–bacteria synergism. A
variety of small-animal models have been used since the 1918
pandemic for this purpose (reviewed in [7]). Most recent
research on secondary bacterial pneumonia has been per-
formed in mice, with variations on a model of pneumococcal
superinfection following inﬂuenza published in 2002 [32]. A
variety of viral and bacterial pathogens have been utilized in
these sequential infection models, including inﬂuenza viruses,
paramyxoviruses [33–35], Staphylococcus aureus [36,37], S. py-
ogenes [28], and H. inﬂuenzae [38]. These models have been
useful platforms for the study of prevention of disease by
vaccines [23], as well as treatment with antiviral [8], antibac-
terial [39] and anti-inﬂammatory drugs [40]. Although mice
have been very useful for exploring the basic mechanisms
underlying the pathogenesis of co-infections, most studies have
been performed with a very limited set of mouse-adapted
laboratory strains, leading to questions about how well the
results can be generalized to more clinically relevant strains.
The use of genetic approaches to isolate speciﬁc virulence
factors and study variations in sequence and related function
has begun to answer some of these questions [41].
In the case of inﬂuenza viruses, evolutionary changes that
occur during adaptation to mammalian hosts appear to greatly
alter the propensity of viruses to support secondary bacterial
infections. All inﬂuenza A viruses are zoonotic pathogens,
sporadically entering humans from wild-bird reservoirs, either
directly or through intermediate hosts such as pigs [42].
Several virological features common in the avian form of these
strains act to promote bacterial superinfections. These include
low levels of glycosylation on the main surface glycoprotein
haemagglutinin (HA), high neuraminidase activity to comple-
ment the decrement in receptor binding afﬁnity associated
with increased HA glycosylation, and expression of an
inﬂammatory PB1-F2 protein [43–46]. As these viruses adapt
to the mammalian lung, either in humans or in pigs, they tend
to lose their disease-associated phenotypes, with increased
glycosylation of the surface proteins, lower neuraminidase
activity, and either mutation to a non-functional form of PB1-
F2 or loss of the active site through introduction of a stop
codon and truncation of the resulting protein (Fig. 2)
FIG. 2. Evolution of viral virulence factors that support secondary
bacterial pneumonia. The schematic shows the typical changes over
time of three virulence factors that support bacterial infections in
animal models. During adaptation to mammalian hosts, inﬂuenza
viruses tend to lose neuraminidase activity, which normally supports
bacterial adherence through removal of sialic acids, which can block
access to bacterial receptors. Similarly, the inﬂammatory activity of
PB1-F2, which potentiates pneumonia, decreases through either
mutation of key C-terminal amino acids or through truncation of the
protein. The presence of key glycans on the surface proteins allows
clearance of viruses from the lower respiratory tract through binding
of collagenous lectins; these accumulate over time, altering the tropism
of viruses from the lower to the upper respiratory tract, and
diminishing viral-mediated effects on bacteria in the deep lung. Overall,
the net effect of these changes is to decrease support for secondary
bacterial infections.
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[43,44,47]. Thus, most pandemic strains that enter humans
directly from birds or after only a short adaptation period in
pigs would be predicted to efﬁciently prime for bacterial
superinfections, whereas well-adapted seasonal strains, includ-
ing inﬂuenza B viruses, would be expected to engender less
secondary disease. It is of note that the 2009 H1N1 pandemic
strain coded for a truncated, non-functional PB1-F2 protein,
which may have contributed to the lower death toll in the
recent pandemic than that associated with bacterial infections
complicating a strain such as the 1918 virus [45,48]. As more
molecular signatures of virulence in the context of the ability
to support secondary bacterial pneumonia are discovered,
surveillance efforts should focus on identifying strains carrying
these signatures as targets for public health concern [49].
Neuraminidase activity has been identiﬁed as a contributor to
secondary bacterial pneumonia following paramyxovirus infec-
tions [33], but speciﬁc predictors of the ability to support
bacterial superinfections for other viruses are currently
unknown.
Variations in the relative contribution to disease during co-
infections involving other viruses or bacteria are less well
established. Animal data suggest that there is strain speciﬁcity
in the ability of S. pneumoniae to cause pneumonia during
inﬂuenza; isolated strains selected from different serotypes
and genotypes had different growth kinetics in the lungs
following inﬂuenza virus infection, resulting in differences in
mortality [50]. Interestingly, these differences were not
apparent in single-agent infections, suggesting a speciﬁcity for
the interaction with the virus rather than simple ampliﬁcation
of inherent virulence. This implies that speciﬁc bacterial
virulence factors, present in some strains but not in others,
are responsible for genotype-related differences in the ability
to interact with inﬂuenza viruses in the lung. These factors may
also contribute to disease in the absence of a viral co-infection,
or they may impact on pathogenesis only in the speciﬁc
situation of superinfection. In the latter case, these virulence
factors are likely to have been missed by traditional virulence
screens in animals, as such screens are performed in ‘clean’
systems, with efforts being made to ensure that no adventi-
tious agents are present. Understanding what these factors are
and how they contribute to virus–bacteria synergism could
form the basis for rational vaccine or drug-related approaches
to the prevention or treatment of pneumonia. Similar data in
mice suggest strain-related differences in the ability of
Staphylococcus aureus to work with inﬂuenza [36]. It is of note
that the USA300 strains that are now commonly causing
fulminant pneumonia in association with inﬂuenza [27] were
highly lethal in association with inﬂuenza in the mouse model
as compared with other strains [36]. Strain-related differences
in other pathogens associated with co-infections have not yet
been studied in animal models or in broader human epidemi-
ological studies.
Implications for Human Disease
On the basis of animal model data, we can form a set of
testable hypotheses about the role of co-infections in human
disease. Expression of speciﬁc virulence factors appears to
drive differences in co-infection models in mice. Although we
know that different bacterial strains differentially code for and
differentially express many virulence factors, little is known
about the spatio-temporal distribution of bacteria by genotype
and the frequency of expression of particular proteins. If there
is signiﬁcant geographical variation in expression of the
bacterial virulence factors associated with secondary pneumo-
nia during viral infections, then one might expect to see
different rates of pneumonia in different locales during
inﬂuenza or other viral epidemics. As a single example,
although there was a high incidence of secondary bacterial
pneumonia in Memphis during the ﬁrst wave of the 2009
pandemic, including ﬁve deaths in children (unpublished data), a
careful study in Milwaukee, a US city of similar size only
620 miles away, demonstrated that bacterial superinfections
were very infrequent and typically mild in the same time frame
[51]. Could differences in the strain distributions of S. pneu-
moniae and Staphylococcus aureus account for these disparate
experiences during the same pandemic?
Addressing these and associated questions will require
signiﬁcant reorganization of bacterial surveillance efforts to
account for both spatial and temporal patterns of bacterial
prevalence. Longitudinal, multi-city and multi-country studies
are necessary, and characterization of isolates must include
advanced sequencing methods to establish genotypes beyond
the simplistic categorizations currently utilized. An improved
understanding of the speciﬁc virulence factors that underlie the
synergism with viruses will also be necessary to guide this
effort, as will the impact of speciﬁc single-nucleotide polymor-
phisms within virulence genes on pathogenesis. Databases that
curate these data must be capable of capturing the relevant
sequence, demographic and geographical information in a form
that is usable for research. Once available, however, these data
will be able to direct vaccine, antiviral and antibacterial
development and application efforts by allowing multiple-
pathogen interactions to be considered, to avoid some of the
pitfalls associated with the single-pathogen paradigm. These
factors should also be taken into account during clinical trials
or preclinical efﬁcacy studies. Secondary bacterial infections,
particularly otitis media and pneumonia, should be considered
as relevant endpoints for the study of both bacterial and viral
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vaccines, and trials of antivirals and antibiotics should consider
the role of viruses and the potential for different outcomes in
single-bacterium infections than in co-infections [39]. Finally,
strain diversity may be a key variable confounding many of
these analyses, and may account for geographical differences in
outcomes and reduce the ability to generalize from one study
site to another.
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